Adalimumab-Induced Epstein-Barr Virus-Related Lymphoproliferative Disorder on FDG PET/CT

被引：0
|
作者：
Ward, John [1 ]
Noy, Ariela [2 ]
Ulaner, Gary [3 ]
Riedl, Christopher [3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Southampton, Hants, England
[2] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, 1275 York Ave, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Nucl Med, 1275 York Ave, New York, NY 10065 USA
来源：
CLINICAL NUCLEAR MEDICINE | 2018年 / 43卷 / 05期
关键词：
F-18-FDG PET; CT; adalimumab; Epstein Barr virus-related lymphoproliferative disorder;
D O I：
10.1097/RLU.0000000000002054
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Adalimumab is a fully human chimeric tumor necrosis factor inhibitor used to treat immune-mediated disorders such as psoriatic arthritis. We present a 51-year-old woman with psoriatic arthritis on methotrexate and infliximab for 12 years. Adalimumab replaced infliximab because of worsening symptoms. Following 3 doses administered 1 week apart, rapidly enlarging cervical lymph nodes developed. Biopsy revealed Epstein-Barr virus-related polymorphic lymphoproliferative disorder. F-18-FDG PET/CT demonstrated widespread hypermetabolic lymphadenopathy; follow-up at 5 weeks off adalimumab revealed almost complete resolution of this adenopathy. This is most consistent with Epstein-Barr virus-related lymphoproliferative disorder secondary to tumor necrosis factor inhibition.
引用
收藏
页码：344 / 345
页数：2
相关论文
共 50 条
  • [1] FDG-PET/CT findings of Epstein-Barr virus-related lymphoproliferative disorders: Pictorial review
    Toriihara, Akira
    Nakajima, Reiko
    Nakadate, Masashi
    Abe, Koichiro
    Kubota, Kazunori
    Ohashi, Isamu
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [2] Epstein-Barr virus-related lymphoproliferative disorders
    Wagner-Johnston N.D.
    Ambinder R.F.
    Current Hematologic Malignancy Reports, 2007, 2 (4) : 249 - 254
  • [3] ANTIVIRAL PROPHYLAXIS AND THE EPSTEIN-BARR VIRUS-RELATED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER
    DAVIS, CL
    HARRISON, KL
    MCVICAR, JP
    FORG, P
    BRONNER, M
    MARSH, CL
    CLINICAL TRANSPLANTATION, 1995, 9 (01) : 53 - 59
  • [4] The Role of Radiation Therapy in Epstein-Barr Virus-Related Lymphoproliferative Disorder
    Barron, D. A.
    Prockop, S. E.
    Wolden, S. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S732 - S733
  • [5] Epstein-Barr virus-related lymphoproliferative disorders of the skin
    Ferrara, Gerardo
    Gualandi, Alberto
    DERMATOLOGY REPORTS, 2024, 16
  • [6] Pathogenesis and FDG-PET/CT findings of Epstein-Barr virus-related lymphoid neoplasms
    Toriihara, Akira
    Nakajima, Reiko
    Arai, Ayako
    Nakadate, Masashi
    Abe, Koichiro
    Kubota, Kazunori
    Tateishi, Ukihide
    ANNALS OF NUCLEAR MEDICINE, 2017, 31 (06) : 425 - 436
  • [7] Reactive Epstein-Barr virus-related polyclonal lymphoproliferative disorder in a patient with AIDS
    Martin, SI
    Zukerberg, L
    Robbins, GK
    CLINICAL INFECTIOUS DISEASES, 2005, 41 (08) : E76 - E79
  • [8] Epstein-Barr virus-related post-transplant lymphoproliferative disorder in the skin
    Yamada, Kazuya
    Motegi, Sei-ichiro
    Amano, Hiroo
    Ishikawa, Osamu
    JOURNAL OF DERMATOLOGY, 2015, 42 (09): : 936 - 937
  • [9] Epstein-Barr virus-related lymphoproliferative disorder induced by equine anti-thymocyte globulin therapy
    Viola, George M.
    Zu, Youli
    Baker, Kelty R.
    Aslam, Saima
    MEDICAL ONCOLOGY, 2011, 28 (04) : 1604 - 1608
  • [10] EPSTEIN-BARR VIRUS-RELATED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS IN THE LETERMOVIR ERA
    Huang, Jingtao
    Wang, Luxiang
    Pan, Zengkai
    Zhang, Zilu
    Huang, Jiayu
    Jiang, Chuanhe
    Hu, Xiaoxia
    BONE MARROW TRANSPLANTATION, 2024, 59 : 424 - 424
12345